Skip to main content
Zhejiang Starry Pharmaceutical Co., Ltd. logo

Zhejiang Starry Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 603520 ISIN · CNE1000026N8 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,502 across all filing types
Latest filing 2025-12-31 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603520

About Zhejiang Starry Pharmaceutical Co., Ltd.

https://www.starrypharm.com/

Zhejiang Starry Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs) and chemical intermediates. The company is a prominent global supplier of X-ray contrast agents, focusing on iodinated media such as Iohexol, Iopamidol, Iodixanol, and Iopromide. In addition to diagnostic imaging agents, its product portfolio includes fluoroquinolone antibiotics like Levofloxacin and Ciprofloxacin. The organization maintains large-scale production facilities compliant with international Good Manufacturing Practice (GMP) standards, serving a diverse clientele of pharmaceutical manufacturers worldwide. By integrating advanced chemical synthesis techniques with rigorous quality control, the company provides essential components for diagnostic imaging and anti-infective therapies.

Recent filings

Filing Released Lang Actions
司太立关于募集资金专户注销的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the cancellation of the special account used for raised funds from a specific stock issuance. It details the background of the fundraising, the account opening, and the account closure. There is no financial statement or detailed financial report included, only a formal notice about the status of the fundraising account and its closure. The document is relatively short (1912 characters) and serves as a formal announcement rather than a full report. This fits the category of Capital/Financing Update (CAP), as it relates to the company's fundraising activities and the management of raised capital.
2025-12-31 Chinese
司太立关于召开2026年第一次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2026 first extraordinary general meeting (临时股东会) of Zhejiang Sitail Pharmaceutical Co., Ltd. It details the meeting date, voting methods, agenda items, and procedural instructions for shareholders. It does not contain financial statements or results but is an announcement of a shareholder meeting and related voting information. This fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document length is 2910 characters, which is consistent with a meeting notice rather than a full report. Therefore, the correct classification is PSI.
2025-12-26 Chinese
司太立关于募集资金投资项目结项、调整投资规模，并将节余募集资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Zhejiang Sitaili Pharmaceutical Co., Ltd. regarding the completion and adjustment of a fundraising investment project and the permanent allocation of surplus raised funds to working capital. It details the fundraising amounts, project investment adjustments, reasons for project termination, and board and sponsor opinions. The document is relatively short (3456 characters) and focuses on the use and adjustment of raised capital rather than presenting comprehensive financial statements or detailed financial performance data. It is not a full annual or interim report, nor an earnings release or management discussion. It is a specific update on capital use and fundraising project status, which fits the category of Capital/Financing Update (CAP).
2025-12-26 Chinese
司太立第五届董事会第十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 19th meeting of the 5th Board of Directors of Zhejiang Sitail Pharmaceutical Co., Ltd. It details the meeting attendance, voting results on specific proposals, and references related announcements about fundraising project completion and the scheduling of an extraordinary general meeting. The content focuses on board decisions and meeting procedures rather than financial results, audit opinions, or shareholder voting outcomes. It is not a full annual or interim report, nor a call transcript or earnings release. The document fits the category of Board/Management Information (MANG) as it announces board meeting resolutions and related corporate governance actions.
2025-12-26 Chinese
国泰海通关于司太立募集资金投资项目结项、调整投资规模，并将节余募集资金永久补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from the sponsor (Guotai Huarong Securities Co., Ltd.) regarding the completion, adjustment of investment scale, and permanent replenishment of working capital from surplus raised funds of Zhejiang Sitail Pharmaceutical Co., Ltd. It includes specific financial figures about the raised funds, project completion status, investment adjustments, and board meeting approvals. The document is focused on the use and management of raised capital, project investment adjustments, and compliance with regulatory requirements. It is not a full annual or interim financial report, nor is it a simple announcement or certification. The content aligns with a Capital/Financing Update as it deals with fundraising project completion, fund usage, and adjustments to investment scale. The document length is 3830 characters, which is substantial and contains detailed financial and project information, not just an announcement or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-12-26 Chinese
司太立关于暂时补充流动资金的募集资金全部归还至募集资金专户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhejiang Sitaili Pharmaceutical Co., Ltd. regarding the temporary use and full repayment of idle raised funds used to supplement working capital. It details the board's approval, the amounts used, and the repayment dates back to the raised funds account. The content focuses on capital usage and repayment, which aligns with updates on company fundraising or capital structure changes. The document length is short (661 characters) and is a direct announcement, not a full financial report or detailed financial statements. Therefore, it fits best under Capital/Financing Update (CAP).
2025-12-22 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.